

5th International Conference of

Orthopedic Surgeons and Rheumatology

June 16-17, 2016 Alicante, Spain

Preclinical development of animal models for rheumatoid arthritis that is more clinically relevant and more focused on targeted therapeutics

Kathy Kane

PharmaLegacy Laboratories, China

In the past two decades, antibody drugs have achieved great success in the treatment of many human diseases, due to their superior efficacies and pharmacokinetic characteristics. Antibody drugs bind to human disease target molecules with great specificity, and do not cross-react with most rodent targets. This has posted a big challenge to the traditional preclinical efficacy evaluation systems, which are mainly based on rodent models. However, antibody drugs can cross-react with most target molecules in Non-human Primate (NHP) models due to the high homology of these NHP targets with their human counterparts. This makes NHP models an ideal system for preclinical efficacy evaluation of antibody therapies. Since 2009, PharmaLegacy has been dedicated to developing a preclinical evaluation system for antibody therapies based on NHP. Now, PharmaLegacy has established a range of NHP models in inflammation/autoimmune and bone disease areas and has successfully evaluated many candidate mAb drugs binding to important disease targets like TNF α /IL-6/IL-1 β and RANKL/Sclerostin. Our experiences have fully demonstrated that NHP models form an ideal preclinical efficacy evaluation system for antibody drugs.

Biography

Kathy Kane is the Director of Business Development for PharmaLegacy. She is a Management Executive with over 14 years' experience in the Biotech Industry in Sales Management and Business Development.

kathy.Kane@pharmalegacy.com**Notes:**